Prof. Dedi Meiri, a lecturer and researcher in the field of medical cannabis at the Technion Institute of Technology, Haifa, and head of its Laboratory of Cancer Biology and Cannabinoid Research in the Biology Faculty, has been appointed as a member of the Scientific Advisory Board of Improdia.
Improdia is developing an innovative blood test that monitors the status of the immune system and enables physicians to identify patients with low immune system activity and whos’ use of medical cannabis will impair the recovery expected from immunotherapy treatment.
Prof. Meiri’s expertise in the field of medical cannabis will greatly contribute to Improdia’s research, which is focusing on developing easily administered blood tests based on proprietary biomarkers that ascertain the status of the immune system in cancer patients receiving treatment combining immunotherapy and medical cannabis. The study is expected to identify patients whos use of medical cannabis will not impair the recovery expected from the immunotherapy.
Improdia’s objective is that health systems, together with the healthinsurance companies, will integrate the test to monitor cancer treatment, thus helping the physicians prevent a decline in the efficacy of immunotherapy due to the combined use of cannabis.